![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
The treatment of metastatic colorectal cancer is evolving. Although the advent of new chemotherapeutic and biologic agents has certainly improved the outlook for many patients, surgical resection in certain subsets of patients with advanced colorectal cancer is the only chance for long-term survival. Traditionally, patients with limited hepatic or pulmonary metastases were the only candidates for metastasectomy. Since hepatic metastases are the most common, there is a tremendous amount of data on the efficacy of this approach and the clinical outcomes. However, more recently, another metastatic site in colorectal cancer has received attention as a potential organ system that can be completely extirpated with improved clinical outcomes. This is the peritoneum, and tumor lesions at this site are referred to as peritoneal surface disease. Macroscopically complete cytoreductive surgery in combination with intraperitoneal hyperthermic chemotherapy for peritoneal surface disease has been demonstrated to produce survival outcomes equal to liver resection for hepatic metastases. This review will examine recent evidence regarding these two surgical oncology paradigms and compare patient populations, clinical outcomes and future challenges.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.